Drug profile · INN
laronidase
ALDURAZYME
laronidase (ALDURAZYME) is a dermatan sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Current US regulatory status: approved.
Drug details — laronidase
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
laronidase (ALDURAZYME) is a dermatan sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Current US regulatory status: approved.
Key facts
Mechanism of action
Dermatan sulfate hydrolytic enzyme
Primary target: Dermatan sulfate
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is laronidase?
laronidase (ALDURAZYME) is a dermatan sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Current US regulatory status: approved.
What is the brand name for laronidase?
ALDURAZYME is a marketed brand name for laronidase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of laronidase?
laronidase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.